Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

NCT02052882 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT02052882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02052882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
January 30, 2014
Completion date
November 13, 2023
Enrollment
60 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

isolated chemotherapy-induced thrombocytopenia